{"id":"https://openalex.org/W2139154837","doi":"https://doi.org/10.1186/1476-4598-12-69","title":"A gene expression profile indicative of early stage HER2 targeted therapy response","display_name":"A gene expression profile indicative of early stage HER2 targeted therapy response","publication_year":2013,"publication_date":"2013-01-01","ids":{"openalex":"https://openalex.org/W2139154837","doi":"https://doi.org/10.1186/1476-4598-12-69","mag":"2139154837","pmid":"https://pubmed.ncbi.nlm.nih.gov/23816254","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/3725168"},"language":"en","primary_location":{"id":"doi:10.1186/1476-4598-12-69","doi":"https://doi.org/10.1186/1476-4598-12-69","is_oa":true,"landing_page_url":"https://doi.org/10.1186/1476-4598-12-69","pdf_url":"https://molecular-cancer.biomedcentral.com/counter/pdf/10.1186/1476-4598-12-69","source":{"id":"https://openalex.org/S132829192","display_name":"Molecular Cancer","issn_l":"1476-4598","issn":["1476-4598"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-3","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320256","host_organization_name":"BioMed Central","host_organization_lineage":["https://openalex.org/P4310320256","https://openalex.org/P4310319965"],"host_organization_lineage_names":["BioMed Central","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://molecular-cancer.biomedcentral.com/counter/pdf/10.1186/1476-4598-12-69","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5101635609","display_name":"Fiona O\u2019Neill","orcid":"https://orcid.org/0000-0002-6935-5171","observed_orcids":["https://orcid.org/0000-0002-6935-5171"]},"institutions":[{"id":"https://openalex.org/I42934936","display_name":"Dublin City University","ror":"https://ror.org/04a1a1e81","country_code":"IE","type":"education","lineage":["https://openalex.org/I42934936"]}],"countries":["IE"],"is_corresponding":true,"raw_author_name":"Fiona O\u2019Neill","raw_affiliation_strings":["Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin, 9, Ireland","School of Nursing and Human Sciences, Dublin City University, Glasnevin, Dublin, 9, Ireland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin, 9, Ireland","institution_ids":["https://openalex.org/I42934936"]},{"raw_affiliation_string":"School of Nursing and Human Sciences, Dublin City University, Glasnevin, Dublin, 9, Ireland","institution_ids":["https://openalex.org/I42934936"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061321901","display_name":"Stephen F. Madden","orcid":"https://orcid.org/0000-0002-0489-4588","observed_orcids":["https://orcid.org/0000-0002-0489-4588"]},"institutions":[{"id":"https://openalex.org/I42934936","display_name":"Dublin City University","ror":"https://ror.org/04a1a1e81","country_code":"IE","type":"education","lineage":["https://openalex.org/I42934936"]}],"countries":["IE"],"is_corresponding":false,"raw_author_name":"Stephen F Madden","raw_affiliation_strings":["Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin, 9, Ireland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin, 9, Ireland","institution_ids":["https://openalex.org/I42934936"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077091444","display_name":"MARTIN M. CLYNES","orcid":"https://orcid.org/0000-0002-3093-8185","observed_orcids":["https://orcid.org/0000-0002-3093-8185","https://orcid.org/0000-0002-1808-5335"]},"institutions":[{"id":"https://openalex.org/I42934936","display_name":"Dublin City University","ror":"https://ror.org/04a1a1e81","country_code":"IE","type":"education","lineage":["https://openalex.org/I42934936"]}],"countries":["IE"],"is_corresponding":false,"raw_author_name":"Martin Clynes","raw_affiliation_strings":["Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin, 9, Ireland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin, 9, Ireland","institution_ids":["https://openalex.org/I42934936"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043292277","display_name":"John Paul Crown","orcid":"https://orcid.org/0000-0002-3125-7613","observed_orcids":["https://orcid.org/0000-0002-3125-7613"]},"institutions":[{"id":"https://openalex.org/I42934936","display_name":"Dublin City University","ror":"https://ror.org/04a1a1e81","country_code":"IE","type":"education","lineage":["https://openalex.org/I42934936"]}],"countries":["IE"],"is_corresponding":false,"raw_author_name":"John Crown","raw_affiliation_strings":["Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin, 9, Ireland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin, 9, Ireland","institution_ids":["https://openalex.org/I42934936"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081858870","display_name":"Padraig Doolan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I42934936","display_name":"Dublin City University","ror":"https://ror.org/04a1a1e81","country_code":"IE","type":"education","lineage":["https://openalex.org/I42934936"]}],"countries":["IE"],"is_corresponding":false,"raw_author_name":"Padraig Doolan","raw_affiliation_strings":["Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin, 9, Ireland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin, 9, Ireland","institution_ids":["https://openalex.org/I42934936"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006350371","display_name":"Sinead T. Aherne","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I42934936","display_name":"Dublin City University","ror":"https://ror.org/04a1a1e81","country_code":"IE","type":"education","lineage":["https://openalex.org/I42934936"]}],"countries":["IE"],"is_corresponding":false,"raw_author_name":"Sin\u00e9ad T Aherne","raw_affiliation_strings":["Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin, 9, Ireland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin, 9, Ireland","institution_ids":["https://openalex.org/I42934936"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5049239189","display_name":"Robert A. O'Connor","orcid":"https://orcid.org/0000-0003-4426-2507","observed_orcids":["https://orcid.org/0000-0003-4426-2507"]},"institutions":[{"id":"https://openalex.org/I42934936","display_name":"Dublin City University","ror":"https://ror.org/04a1a1e81","country_code":"IE","type":"education","lineage":["https://openalex.org/I42934936"]}],"countries":["IE"],"is_corresponding":false,"raw_author_name":"Robert O\u2019Connor","raw_affiliation_strings":["Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin, 9, Ireland","School of Nursing and Human Sciences, Dublin City University, Glasnevin, Dublin, 9, Ireland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin, 9, Ireland","institution_ids":["https://openalex.org/I42934936"]},{"raw_affiliation_string":"School of Nursing and Human Sciences, Dublin City University, Glasnevin, Dublin, 9, Ireland","institution_ids":["https://openalex.org/I42934936"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5101635609"],"corresponding_institution_ids":["https://openalex.org/I42934936"],"apc_list":{"value":5090,"currency":"USD","value_usd":5090},"apc_paid":{"value":5090,"currency":"USD","value_usd":5090},"fwci":1.4304,"has_fulltext":true,"cited_by_count":24,"citation_normalized_percentile":{"value":0.80010736,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"12","issue":"1","first_page":"69","last_page":"69"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/her2-targeted-therapy","display_name":"HER2-targeted therapy","score":0.9240000247955322},{"id":"https://openalex.org/keywords/predictive-biomarkers","display_name":"predictive biomarkers","score":0.9350000023841858},{"id":"https://openalex.org/keywords/gene-expression-profiling","display_name":"gene expression profiling","score":0.6790000200271606},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.8199999928474426},{"id":"https://openalex.org/keywords/lapatinib","display_name":"lapatinib","score":0.9869999885559082},{"id":"https://openalex.org/keywords/afatinib","display_name":"afatinib","score":0.9739999771118164},{"id":"https://openalex.org/keywords/neratinib","display_name":"neratinib","score":1.0},{"id":"https://openalex.org/keywords/trastuzumab","display_name":"trastuzumab","score":0.9950000047683716},{"id":"https://openalex.org/keywords/gefitinib","display_name":"gefitinib","score":0.8769999742507935},{"id":"https://openalex.org/keywords/breast-cancer-cell-lines","display_name":"breast cancer cell lines","score":0.8240000009536743},{"id":"https://openalex.org/keywords/drug-sensitivity","display_name":"drug sensitivity","score":0.699999988079071},{"id":"https://openalex.org/keywords/rb1cc1","display_name":"RB1CC1","score":0.9369999766349792},{"id":"https://openalex.org/keywords/her3","display_name":"HER3","score":0.9950000047683716},{"id":"https://openalex.org/keywords/foxo3","display_name":"FOXO3","score":0.9779999852180481},{"id":"https://openalex.org/keywords/nr3c1","display_name":"NR3C1","score":0.9919999837875366},{"id":"https://openalex.org/keywords/ccnd1","display_name":"CCND1","score":0.9700000286102295},{"id":"https://openalex.org/keywords/egfr-inhibitors","display_name":"EGFR inhibitors","score":0.5789999961853027},{"id":"https://openalex.org/keywords/dasatinib","display_name":"dasatinib","score":0.6809999942779541},{"id":"https://openalex.org/keywords/epirubicin","display_name":"epirubicin","score":0.8809999823570251},{"id":"https://openalex.org/keywords/capecitabine","display_name":"capecitabine","score":0.984000027179718}],"concepts":[{"id":"https://openalex.org/C2777329042","wikidata":"https://www.wikidata.org/wiki/Q420323","display_name":"Lapatinib","level":5,"score":0.9568315744400024},{"id":"https://openalex.org/C2779413316","wikidata":"https://www.wikidata.org/wiki/Q6995920","display_name":"Neratinib","level":5,"score":0.9093178510665894},{"id":"https://openalex.org/C2780586478","wikidata":"https://www.wikidata.org/wiki/Q4688818","display_name":"Afatinib","level":5,"score":0.8958243131637573},{"id":"https://openalex.org/C2780580887","wikidata":"https://www.wikidata.org/wiki/Q417824","display_name":"Gefitinib","level":4,"score":0.7173030376434326},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5832809805870056},{"id":"https://openalex.org/C191560914","wikidata":"https://www.wikidata.org/wiki/Q7390592","display_name":"SKBR3","level":5,"score":0.5568029880523682},{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.5371150970458984},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.5189914107322693},{"id":"https://openalex.org/C2778820342","wikidata":"https://www.wikidata.org/wiki/Q906415","display_name":"Tyrosine-kinase inhibitor","level":3,"score":0.4642074704170227},{"id":"https://openalex.org/C2779251935","wikidata":"https://www.wikidata.org/wiki/Q5385089","display_name":"ErbB","level":3,"score":0.4469524621963501},{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.4409123659133911},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4227748215198517},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.36220550537109375},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.361733078956604},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.33228015899658203},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.326223224401474},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.30625689029693604},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.28881803154945374},{"id":"https://openalex.org/C2994423619","wikidata":"https://www.wikidata.org/wiki/Q9103","display_name":"Human breast","level":4,"score":0.0}],"mesh":[{"descriptor_ui":"D000077341","descriptor_name":"Lapatinib","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077716","descriptor_name":"Afatinib","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D011804","descriptor_name":"Quinolines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D013997","descriptor_name":"Time Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015972","descriptor_name":"Gene Expression Regulation, Neoplastic","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D018719","descriptor_name":"Erb-b2 Receptor Tyrosine Kinases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D018719","descriptor_name":"Erb-b2 Receptor Tyrosine Kinases","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D020128","descriptor_name":"Inhibitory Concentration 50","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020869","descriptor_name":"Gene Expression Profiling","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false}],"locations_count":5,"locations":[{"id":"doi:10.1186/1476-4598-12-69","doi":"https://doi.org/10.1186/1476-4598-12-69","is_oa":true,"landing_page_url":"https://doi.org/10.1186/1476-4598-12-69","pdf_url":"https://molecular-cancer.biomedcentral.com/counter/pdf/10.1186/1476-4598-12-69","source":{"id":"https://openalex.org/S132829192","display_name":"Molecular Cancer","issn_l":"1476-4598","issn":["1476-4598"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-3","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320256","host_organization_name":"BioMed Central","host_organization_lineage":["https://openalex.org/P4310320256","https://openalex.org/P4310319965"],"host_organization_lineage_names":["BioMed Central","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:2716182","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/3725168","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},{"id":"pmid:23816254","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/23816254","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular cancer","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:3725168","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3725168/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Mol Cancer","raw_type":"Text"},{"id":"pmh:oai:www.lenus.ie:10147/298261","doi":null,"is_oa":true,"landing_page_url":"http://hdl.handle.net/10147/298261","pdf_url":null,"source":{"id":"https://openalex.org/S4306401756","display_name":"Lenus, The Irish Health Repository (Dr Steevens Hospital Library)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1186/1476-4598-12-69","doi":"https://doi.org/10.1186/1476-4598-12-69","is_oa":true,"landing_page_url":"https://doi.org/10.1186/1476-4598-12-69","pdf_url":"https://molecular-cancer.biomedcentral.com/counter/pdf/10.1186/1476-4598-12-69","source":{"id":"https://openalex.org/S132829192","display_name":"Molecular Cancer","issn_l":"1476-4598","issn":["1476-4598"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-3","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320256","host_organization_name":"BioMed Central","host_organization_lineage":["https://openalex.org/P4310320256","https://openalex.org/P4310319965"],"host_organization_lineage_names":["BioMed Central","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9537000060081482,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2139154837.pdf","grobid_xml":"https://content.openalex.org/works/W2139154837.grobid-xml"},"referenced_works_count":33,"referenced_works":["https://openalex.org/W51995314","https://openalex.org/W1979688926","https://openalex.org/W1982729445","https://openalex.org/W1990097438","https://openalex.org/W1990953009","https://openalex.org/W2010938071","https://openalex.org/W2020372547","https://openalex.org/W2050156776","https://openalex.org/W2061349734","https://openalex.org/W2063391304","https://openalex.org/W2067191435","https://openalex.org/W2076616438","https://openalex.org/W2076912549","https://openalex.org/W2083000476","https://openalex.org/W2086578539","https://openalex.org/W2096122358","https://openalex.org/W2096164879","https://openalex.org/W2107277218","https://openalex.org/W2109439031","https://openalex.org/W2110354540","https://openalex.org/W2110444464","https://openalex.org/W2114095518","https://openalex.org/W2114941442","https://openalex.org/W2138095640","https://openalex.org/W2141393790","https://openalex.org/W2142752401","https://openalex.org/W2145477245","https://openalex.org/W2148479421","https://openalex.org/W2149952977","https://openalex.org/W2161428561","https://openalex.org/W2162232981","https://openalex.org/W2168734527","https://openalex.org/W3193354671"],"related_works":["https://openalex.org/W2604573213","https://openalex.org/W2162232981","https://openalex.org/W3122351251","https://openalex.org/W3131738825","https://openalex.org/W2991786365","https://openalex.org/W2015878053","https://openalex.org/W2603632157","https://openalex.org/W2331169376","https://openalex.org/W1991253169","https://openalex.org/W4220930711"],"abstract_inverted_index":{"BACKGROUND:":[0],"Efficacious":[1],"application":[2],"of":[3,9,22,31,50,54,64,73,92,105,125,203,211,218,229,235,247],"HER2-targetting":[4],"agents":[5],"requires":[6],"the":[7,47,90,103,116,126,144,201,204,208,212,230],"identification":[8],"novel":[10],"predictive":[11],"biomarkers.":[12],"Lapatinib,":[13],"afatinib":[14,83,187],"and":[15,24,43,46,77,84,96,149,159,167,188,194,233],"neratinib":[16,85,148],"are":[17],"tyrosine":[18],"kinase":[19],"inhibitors":[20],"(TKIs)":[21],"HER2":[23,74,117,209,237],"EGFR":[25],"growth":[26],"factor":[27],"receptors.":[28],"A":[29,137],"panel":[30,53],"breast":[32],"cancer":[33],"cell":[34,79,121,182,205],"lines":[35,80,206],"was":[36,58,141],"treated":[37],"with":[38,81,102,146],"these":[39,180,219,248],"agents,":[40],"trastuzumab,":[41],"gefitinib":[42],"cytotoxic":[44],"therapies":[45],"expression":[48,91,108,139,175,197,216],"pattern":[49,109,140,176],"a":[51,61,172,192,224],"specific":[52,195,245],"genes":[55,220],"using":[56],"RT-PCR":[57],"investigated":[59],"as":[60],"potential":[62],"marker":[63],"early":[65,227],"drug":[66,135],"response":[67,99,133,239],"to":[68,113,134,157,200,207],"HER2-targeting":[69],"therapies.":[70],"RESULTS:":[71],"Treatment":[72],"TKI-sensitive":[75],"SKBR3":[76],"BT474":[78],"lapatinib,":[82,185],"induced":[86,213],"an":[87,130],"increase":[88],"in":[89,115,171,215,240],"RB1CC1,":[93],"ERBB3,":[94],"FOXO3a":[95],"NR3C1.":[97],"The":[98],"directly":[100],"correlated":[101],"degree":[104],"sensitivity.":[106],"This":[107],"switched":[110],"from":[111],"up-regulated":[112],"down-regulated":[114],"expressing,":[118],"HER2-TKI":[119],"insensitive":[120],"line":[122,183],"MDAMB453.":[123],"Expression":[124],"CCND1":[127],"gene":[128,196],"demonstrated":[129],"inversely":[131],"proportional":[132],"exposure.":[136],"similar":[138],"observed":[142],"following":[143,155],"treatment":[145,169,190],"both":[147],"afatinib.":[150],"These":[151],"patterns":[152],"were":[153],"retained":[154],"exposure":[156],"traztuzumab":[158],"lapatinib":[160],"plus":[161],"capecitabine.":[162],"In":[163,179],"contrast,":[164],"gefitinib,":[165],"dasatinib":[166],"epirubicin":[168],"resulted":[170],"completely":[173],"different":[174],"change.":[177],"CONCLUSIONS:":[178],"HER2-expressing":[181],"models,":[184],"neratinib,":[186],"trastuzumab":[189],"generated":[191],"characteristic":[193],"response,":[198],"proportionate":[199],"sensitivity":[202],"inhibitor.Characterisation":[210],"changes":[214],"levels":[217],"may":[221],"therefore":[222],"give":[223],"valuable,":[225],"very":[226],"predictor":[228],"likely":[231],"extent":[232],"specificity":[234],"tumour":[236],"inhibitor":[238],"patients,":[241],"potentially":[242],"guiding":[243],"more":[244],"use":[246],"agents.":[249]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":2},{"year":2022,"cited_by_count":2},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":3},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":4},{"year":2014,"cited_by_count":4}],"updated_date":"2026-11-13T13:42:25.865203","created_date":"2016-06-24T00:00:00"}